AIMS-Medical S.L. Obtains Funding to Boost its Technology.
At AIMS-Medical we are back from holidays with good news. The spin-off has been awarded funding from the “Start-up Capital for Emerging Technology Companies 2023” call by ACCIÓ, a recognition of our commitment to innovation in medical technology.
The company’s core mission is to develop mass #screening technologies that empower healthcare professionals to improve the diagnosis of diseases related to geriatric syndromes. Our innovative approach is based on a platform of clinical diagnostic support services based on Artificial Intelligence, which uses supervised machine learning methods to predict the risk of suffering one or more pathologies in hospitalised and primary care patients, using clinical data that ensures patient privacy.
Our roadmap includes expanding our platform to address other diseases that often go undetected and under-diagnosed, and we are also committed to job creation in key areas such as engineering and biomedicine.
This funding not only propels AIMS-Medical S.L. into the future, but also contributes to addressing critical health challenges and promotes the sustainability of the healthcare system.
